✦ LIBER ✦
The incidence of arthropathy adverse events in efalizumab-treated patients is low and similar to placebo and does not increase with long-term treatment: pooled analysis of data from Phase III clinical trials of efalizumab
✍ Scribed by Carlo Pincelli; Eric Henninger; Florence Casset-Semanaz
- Publisher
- Springer-Verlag
- Year
- 2006
- Tongue
- English
- Weight
- 475 KB
- Volume
- 298
- Category
- Article
- ISSN
- 0340-3696
No coin nor oath required. For personal study only.